Tango Therapeutics, Inc.
TNGX
$25.60
-$0.05-0.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 121.47% | 39.04% | 48.29% | 53.28% | -42.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 121.47% | 39.04% | 48.29% | 53.28% | -42.84% |
| Cost of Revenue | -2.05% | -9.16% | -8.17% | -5.18% | 0.92% |
| Gross Profit | 28.81% | 28.67% | 31.49% | 31.08% | -20.99% |
| SG&A Expenses | 25.20% | 1.57% | -5.12% | 2.57% | 13.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.72% | -6.60% | -7.46% | -3.41% | 3.79% |
| Operating Income | 13.31% | 19.43% | 23.56% | 21.02% | -18.75% |
| Income Before Tax | 14.86% | 18.78% | 21.91% | 18.49% | -25.00% |
| Income Tax Expenses | -136.63% | -114.36% | -98.08% | -47.57% | -1.71% |
| Earnings from Continuing Operations | 15.01% | 18.93% | 22.03% | 18.54% | -24.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.01% | 18.93% | 22.03% | 18.54% | -24.96% |
| EBIT | 13.31% | 19.43% | 23.56% | 21.02% | -18.75% |
| EBITDA | 13.16% | 19.51% | 23.82% | 21.35% | -19.11% |
| EPS Basic | 36.95% | 32.40% | 28.07% | 21.77% | -17.33% |
| Normalized Basic EPS | 35.95% | 31.21% | 27.38% | 24.33% | -14.61% |
| EPS Diluted | 36.02% | 31.38% | 27.06% | 20.74% | -17.44% |
| Normalized Diluted EPS | 35.31% | 30.50% | 26.67% | 23.62% | -14.61% |
| Average Basic Shares Outstanding | 22.37% | 13.97% | 6.85% | 4.33% | 6.64% |
| Average Diluted Shares Outstanding | 23.92% | 15.53% | 8.43% | 5.94% | 6.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |